(b).
Overall survival | Progression-free survival | |||||
---|---|---|---|---|---|---|
HR | 95% CI | p | HR | 95% CI | p | |
UrC type | ||||||
Adenocarcinoma | 2.031 | 0.452–9.117 | 0.355 | 4.782 | 0.626–36.506 | 0.131 |
Nonadenocarcinoma | ref. | ref. | ||||
UrC adenocarcinoma | ||||||
Mucinous | 0.888 | 0.192–4.095 | 0.879 | 0.736 | 0.203–2.667 | 0.641 |
Nonmucinous | ref. | ref. | ||||
UrC nonadenocarcinoma | ||||||
UC | n/a∗ | n/a∗ | n/a∗ | n/a∗ | n/a∗ | n/a∗ |
Non-UC | ref. | ref. | ||||
Gender | ||||||
Male | 0.629 | 0.276–1.430 | 0.268 | 0.197 | 0.039–0.981 | 0.047 |
Female | ref. | ref. | ||||
Age^ | ||||||
<45 years | 1.880 | 0.769–4.598 | 0.167 | 1.534 | 0.652–3.610 | 0.327 |
>45 years | ref. | ref. | ||||
Tumor size^ | ||||||
<7.0 cm | 2.644 | 0.502–13.923 | 0.251 | 2.943 | 0.592–14.622 | 0.187 |
>7.0 cm | ref | ref. |